Pre-Symptomatic Dawn-Administration for Phase-Advance Targeting
🧪 Overview
Morning administration of 0.3-0.5mg melatonin in early cognitive decline produces circadian phase advances that counteract AD-associated rhythm fragmentation. However, this hypothesis contradicts established chronobiology—melatonin in the morning typically causes phase delays not advances in most individuals. The Lewy et al. (1998) citation involves evening administration for phase advance, not morning. Morning melatonin administration studies in humans typically show sedation and circadian disruption rather than advances. Circadian fragmentation in AD is heterogeneous (some advanced, some delayed, some arrhythmic). Blanket morning administration ignores this heterogeneity. This hypothesis is contraindicated by basic chronobiology.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["MT2 Melatonin Receptor<br/>PER1/2 Circadian Phase"]
B["Dawn Administration<br/>Chronotherapy Timing"]
C["SCN Pacemaking<br/>Phase Advance"]
D["Circadian Oscillation<br/>Normalization"]
E["AD Pathology<br/>Pre-Symptomatic Delay"]
F["Phase-Advance<br/>Targeting Window"]
G["Chronotherapy as<br/>AD Prevention Strategy"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"informs"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — MT2
No curated PDB or AlphaFold mapping for MT2 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MT2 receptor (Gq.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF early cognitive decline patients receive 0.3-0.5mg oral melatonin within 30 minutes of waking for 14 consecutive days, THEN their circadian phase will shift DELAYED by ≥20 minutes as measured by di | Phase delay of ≥20 minutes in ≥70% of participants, opposite to the hypothesized advance | — no observation — | pending | 0.15 |
| IF patients are stratified by baseline circadian phase status (advanced, delayed, or arrhythmic via ambulatory core body temperature nadir), THEN morning melatonin will produce heterogeneous phase res | Non-uniform response across strata; predominantly delayed or arrhythmic outcomes in non-delayed subgroups, contradicting blanket morning administration | — no observation — | pending | 0.18 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |